Relationship between matrix metalloproteinases/tissue inhibitors of matrix metalloproteinases systems and autoantibody patterns in systemic sclerosis.

[1]  A. Gabrielli,et al.  Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. , 2006, The New England journal of medicine.

[2]  F. Tan.  Autoantibodies against PDGF receptor in scleroderma. , 2006, The New England journal of medicine.

[3]  J. Senécal,et al.  DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. , 2006, Arthritis and rheumatism.

[4]  R. Corrocher,et al.  Antibodies against Human Cytomegalovirus in the Pathogenesis of Systemic Sclerosis: A Gene Array Approach , 2005, PLoS medicine.

[5]  Sung-Hwan Park,et al.  Elevated matrix metalloproteinase-9 in patients with systemic sclerosis , 2004, Arthritis research & therapy.

[6]  M. Tremblay,et al.  Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis. , 2004, Arthritis and rheumatism.

[7]  Z. Werb,et al.  Regulation of matrix biology by matrix metalloproteinases. , 2004, Current opinion in cell biology.

[8]  S. Jimenez,et al.  Systemic sclerosis: current views of its pathogenesis. , 2003, Autoimmunity reviews.

[9]  T. Medsger,et al.  Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. , 2003, Arthritis and rheumatism.

[10]  T. Medsger,et al.  Assessment of disease severity and prognosis. , 2003, Clinical and experimental rheumatology.

[11]  J. Seibold,et al.  Assessment of skin, joint, tendon and muscle involvement. , 2003, Clinical and experimental rheumatology.

[12]  E. Tuzcu,et al.  Relation of matrix-metalloproteinase 3 found in coronary lesion samples retrieved by directional coronary atherectomy to intravascular ultrasound observations on coronary remodeling. , 2002, The American journal of cardiology.

[13]  Z. Werb,et al.  How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.

[14]  G. Murphy,et al.  Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls. , 2001, Annals of the rheumatic diseases.

[15]  A. Silman,et al.  European multicentre study to define disease activity criteria for systemic sclerosis.* II. Identification of disease activity variables and development of preliminary activity indexes , 2001, Annals of the rheumatic diseases.

[16]  M. Fujimoto,et al.  Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis. , 2000, Journal of the American Academy of Dermatology.

[17]  M. Jayson,et al.  Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin , 1999, The Journal of pathology.

[18]  B. Giraudeau,et al.  Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis? , 1999, Chest.

[19]  M. Hoshino,et al.  Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. , 1999, The Journal of allergy and clinical immunology.

[20]  A. Kossakowska,et al.  Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. , 1998, The American journal of pathology.

[21]  F. Kondo,et al.  Immunohistochemical Study of Transforming Growth Factor‐p 1, Matrix Metalloproteinase‐2,9, Tissue Inhibitors of Metalloproteinase‐1,2, and Basement Membrane Components at Pancreatic Ducts in Chronic Pancreatitis , 1998, Pancreas.

[22]  M. Kitaichi,et al.  Localization of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[23]  Z. Werb.  ECM and Cell Surface Proteolysis: Regulating Cellular Ecology , 1997, Cell.

[24]  Y. Okada,et al.  Research communicationA one-step sandwich enzyme immunoassay for human matrix metalloproteinase 8 (neutrophil collagenase) using monoclonal antibodies , 1996 .

[25]  C. Plumpton,et al.  Development of an enzyme-linked immunosorbent assay to measure total TIMP-1 (free TIMP-1 and TIMP-1 in combination with matrix-metalloproteinases) and measurement of TIMP 1 and CRP in serum. , 1995, Clinica chimica acta; international journal of clinical chemistry.

[26]  U. Moll,et al.  Plasma assay of gelatinase B:Tissue inhibitor of metalloproteinase complexes in cancer , 1995, Cancer.

[27]  K. Takeda,et al.  Decreased collagenase expression in cultured systemic sclerosis fibroblasts. , 1994, The Journal of investigative dermatology.

[28]  D. Denhardt,et al.  Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. , 1993, Pharmacology & therapeutics.

[29]  Y. Okada,et al.  A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 3 (stromelysin-1) using monoclonal antibodies. , 1992, Clinica chimica acta; international journal of clinical chemistry.

[30]  L. Liotta,et al.  Immunoassay of type IV collagenase/gelatinase (MMP-2) in human plasma. , 1992, Journal of immunological methods.

[31]  K. Iwata,et al.  Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases. An application for rheumatoid arthritis serum and plasma. , 1990, Journal of immunological methods.

[32]  K. Tomita,et al.  Immunolocalization of matrix metalloproteinase 3 (stromelysin) in rheumatoid synovioblasts (B cells): correlation with rheumatoid arthritis. , 1989, Annals of the rheumatic diseases.

[33]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[34]  S. Jimenez,et al.  Increased biosynthesis of glycosaminoglycans by scleroderma fibroblasts in culture. , 1984, Arthritis and rheumatism.

[35]  R. Timpl,et al.  Variability in collagen and fibronectin synthesis by scleroderma fibroblasts in primary culture. , 1981, The Journal of investigative dermatology.

[36]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[37]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[38]  A. Eisen,et al.  Scleroderma: increased biosynthesis of triple-helical type I and type III procollagens associated with unaltered expression of collagenase by skin fibroblasts in culture. , 1979, The Journal of clinical investigation.

[39]  E. Leroy,et al.  Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. , 1974, The Journal of clinical investigation.